Clinical Trial Update: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Talquetamab plus Pomalidomide, Talquetamab plus Teclistamab, and Elotuzumab plus Pomalidomide and Dexamethasone or Pomalidomide, Borte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Pomalidomide (Pomalidomide)
• Talquetamab (talquetamab)
• Teclistamab (teclistamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING